cbdMD, Inc. Share Price

YCBD

US12482W4087

Pharmaceuticals

Market Closed - NYSE 21:00:00 18/09/2026 BST			5-day change	1st Jan Change
0.4501 ^USD	-9.98%		-5.84%	-66.66%

09-02	CbdMD, Inc. entered into a definitive asset purchase agreement to acquire Operating assets and brands of Twinlab Consolidation Corporation for $2.9 million.	CI
08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT

Last Transcript: cbdMD, Inc.

CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026

08-13

More transcripts

Analysts' recommendations: cbdMD, Inc.

08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
05/10/23	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
18/06/21	CbdMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Managers and Directors: cbdMD, Inc.

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	28/02/2023
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	31/12/2018
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Bakari Sellers BRD	Director/Board Member	41	28/02/2017
William Raines BRD	Director/Board Member	66	18/04/2019
Scott Stephen CHM	Chairman	60	02/06/2022

More insiders

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
18/09/26	US$0.4501	-9.98%	4,512,349
17/09/26	US$0.5000	+7.30%	787,790
16/09/26	US$0.4660	+1.29%	48,781
15/09/26	US$0.4601	-3.57%	112,489
14/09/26	US$0.4771	-1.06%	22,703

Delayed Quote NYSE

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.4501

Average target price

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	5.6M 4.88M 4.6M 4.18M 7.83M 537M 7.87M 55.07M 21.27M 273M 21.04M 20.58M 879M	P/E 2026 *	-1.52x	P/E 2027 *	-2.63x
Enterprise Value	5.6M 4.88M 4.6M 4.18M 7.83M 537M 7.87M 55.07M 21.27M 273M 21.04M 20.58M 879M	EV / Sales 2026 *	0.26x	EV / Sales 2027 *	0.2x
Free-Float	90%	Yield 2026 *	-	Yield 2027 *	-

09-02	CbdMD, Inc. entered into a definitive asset purchase agreement to acquire Operating assets and brands of Twinlab Consolidation Corporation for $2.9 million.	CI
08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
08-13	CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026
08-13	CbdMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI
07-14	CbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina	CI
07-14	CbdMD Expands Oasis Beverage Distribution to South Carolina	MT
07-07	Cbdmd Completes Self-Affirmed Gras Determination for Broad Spectrum Cbd	CI
07-01	CbdMD Launches Oasis Mixer, A Hemp-Derived Zero-Proof THC Spirit	CI
06-16	CbdMD, Inc. Appoints Wade Brown as Chief Marketing Officer	CI
05-14	CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026
05-14	CbdMD reports 19% year-over-year and 12% sequential revenue growth	RE
05-14	CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-06	Hawkeye Systems, Inc. Announces President and Directorate Appointments	CI

09-02	CbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness	PR
08-13	CbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026	PR
08-10	CbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results	PR
08-03	CbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products	PR
07-27	CbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access	AQ

1 day	-9.98%
1 week	-5.84%
Current month	-8.14%
1 month	-5.24%
3 months	-34.48%
6 months	-40.19%
Current year	-66.66%

1 week	0.45	0.58
1 month	0.45	0.58
Current year	0.45	1.34
1 year	0.45	2.56
3 years	0.45	13.84
5 years	0.45	770.4
10 years	0.45	2,606.4

cbdMD, Inc. Share Price

Stocks

YCBD

US12482W4087

Pharmaceuticals

Valuation: cbdMD, Inc.

Chart: cbdMD, Inc.

Latest news: cbdMD, Inc.

Last Transcript: cbdMD, Inc.

Analysts' recommendations: cbdMD, Inc.

Press Releases: cbdMD, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: cbdMD, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/04/26	Jeffrey Porter	Free	Director	1,572	0.0150%
14/04/26	William Raines	Free	Director	1,572	0.0150%
14/04/26	Bakari Sellers	Free	Director	1,572	0.0150%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CBDMD, INC.	-9.98%	-5.84%	-34.86%	-95.83%	5.6M
ELI LILLY AND COMPANY	+0.04%	+2.67%	+51.68%	+100.28%	1,027B
JOHNSON & JOHNSON	-0.09%	+1.37%	+52.36%	+67.23%	651B
ABBVIE INC.	-0.02%	+3.51%	+19.54%	+73.52%	467B
ROCHE HOLDING AG	-1.22%	+3.27%	+37.02%	+36.52%	350B
NOVARTIS AG	-0.79%	+2.64%	+19.18%	+24.76%	268B
ASTRAZENECA PLC	+0.58%	+6.31%	+9.69%	+14.26%	257B
AMGEN INC.	+1.55%	+0.83%	+40.38%	+47.92%	205B
NOVO NORDISK A/S	+0.79%	-1.66%	-23.80%	-57.76%	190B
GILEAD SCIENCES, INC.	-0.52%	+3.66%	+33.72%	+98.37%	187B
Average	-0.96%	+2.70%	+20.49%	+30.93%	360.21B
Weighted average by Cap.	-0.01%	+2.62%	+35.25%	+61.48%

	2026 *	2027 *
Net sales	21.92M 19.09M 18.02M 16.37M 30.65M 2.1B 30.8M 215M 83.23M 1.07B 82.35M 80.52M 3.44B	28.6M 24.9M 23.5M 21.35M 39.98M 2.74B 40.18M 281M 109M 1.39B 107M 105M 4.49B
Net income	-3.33M -2.9M -2.74M -2.49M -4.66M -319M -4.68M -32.75M -12.65M -162M -12.52M -12.24M -523M	-4.95M -4.31M -4.06M -3.69M -6.92M -474M -6.95M -48.61M -18.78M -241M -18.58M -18.17M -776M
Net Debt	-	-

Markets		Quality
NYSE	YCBD	Delayed
CBOE	YCBD	Real-time